This study will examine the effects a Glucagon Receptor Antagonist (GRA), has on Insulin
Sensitivity, Cardiovascular risks (CVD), and Ketone body formation in participants with Type
1 diabetes. The participants will complete blood tests, tests to measure energy expenditure,
CVD risks, and insulin resistance. These tests will be performed prior to start of treatment
and again after 12-weeks of treatment with the GRA (called REMD-477).